Results 111 to 120 of about 4,267 (193)

Dynamic N1-Methyladenosine in Plant Messenger RNA [PDF]

open access: yesPlant Physiology, 2020
Deposition of different chemical groups onto RNA generates diverse RNA modifications. All types of prokaryotic and eukaryotic RNA can undergo modifications. For example, methylation of the adenosine bases at the nitrogen-6 or nitrogen-1 position generates N6-methyladenosine (m6A) and N1-
openaire   +2 more sources

Trans‐Omics Integration Reveals That the Kidney Contributes to Systemic Aging via Sexually Dimorphic Accumulation of Glycosphingolipids

open access: yesMedComm, Volume 7, Issue 3, March 2026.
Female‐specific renal GluCer accumulation disrupts mitochondrial quality control via a conserved purine‐mTORC1 pathway, triggering a wave of uremic toxins into the systemic circulation that constitutes a female‐biased vulnerability toward renal‐driven multiorgan senescence.
Zhen Ni   +18 more
wiley   +1 more source

RNA modifications and their role in gene expression

open access: yesFrontiers in Molecular Biosciences
Post-transcriptional RNA modifications have recently emerged as critical regulators of gene expression programs. Understanding normal tissue development and disease susceptibility requires knowledge of the various cellular mechanisms which control gene ...
I. Made Artika   +4 more
doaj   +1 more source

Identification and characterization of the RNA modifying factors PUS7 and WTAP as key components for the control of tumor biological processes in renal cell carcinomas [PDF]

open access: yes
Current research discusses the putative importance of RNA modification in tumor diseases. These RNA modifications include predominantly pseudouridinylation, ortho-methylations on the ribose residues, as well as methylations on the organic bases.
Dehghani, Faramarz   +4 more
core   +1 more source

Molecular Insights into RNA Modifications and their Role in Shaping Immune Responses and Tumor Microenvironments [PDF]

open access: yes
RNA modifications play crucial roles in immune system development and function, with dynamic changes essential for diverse cellular processes. Innovative profiling technologies are invaluable for understanding the significance of these modifications in ...
Ajmal, Tehreem   +9 more
core   +1 more source

Killing The Messenger: Exploring Novel Triggers For Messenger Rna Decay In Eukaryotes [PDF]

open access: yes, 2017
The lifecycle of messenger RNAs is regulated by multiple layers beyond their primary sequence. In addition to carrying the information for protein synthesis, mRNAs are decorated with RNA binding proteins, marked with covalent chemical modifications, and ...
Vandivier, Lee Elliott
core   +1 more source

Epitranscriptomic code and its alterations in human disease [PDF]

open access: yes, 2018
Innovations in epitranscriptomics have resulted in the identification of more than 160 RNA modifications to date. These developments, together with the recent discovery of writers, readers, and erasers of modifications occurring across a wide range of ...
Janga, Sarath Chandra   +1 more
core   +1 more source

Adapting nanopore sequencing basecalling models for modification detection via incremental learning and anomaly detection

open access: yesNature Communications
We leverage machine learning approaches to adapt nanopore sequencing basecallers for nucleotide modification detection. We first apply the incremental learning (IL) technique to improve the basecalling of modification-rich sequences, which are usually of
Ziyuan Wang   +7 more
doaj   +1 more source

Clinical Perspectives in Epitranscriptomics [PDF]

open access: yes
Epitranscriptomics, the study of reversible and dynamic chemical marks on the RNA, is rapidly emerging as a pivotal field in post-transcriptional gene expression regulation.
Esteller, Manel   +2 more
core   +1 more source

Involvement of N1-Methyladenosine (m1A) in the mitochondrial ND5 mRNA and the corresponding writer enzyme TRMT10C in Alzheimer's disease

open access: yes, 2023
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the most common form of dementia. Even though the U.S. Food and Drug Administration (FDA) this year approved a new antibody that may moderately decelerate cognitive decline, there is still no treatment that can halt or even reverse the symptoms of AD. Apart from the prime suspects (
openaire   +3 more sources

Home - About - Disclaimer - Privacy